GILD — Gilead Sciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Gilead Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	24,689	27,305	27,281	27,116	28,754
Cost of Revenue
Gross Profit	20,117	20,704	21,624	21,097	22,503
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	20,618	17,387	19,951	19,511	27,092
Operating Profit	4,071	9,918	7,330	7,605	1,662
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,669	8,278	5,814	6,859	690
Provision for Income Taxes
Net Income After Taxes	89	6,201	4,566	5,612	479
Minority Interest
Net Income Before Extraordinary Items
Net Income	123	6,225	4,592	5,664	479
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	123	6,225	4,592	5,665	480
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.73	5.07	6.78	6.15	7.61
Dividends per Share